Cath Lab Digest

1. Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004;39(7):885-910.
2. Game FL, Jeffcoate WJ. Primarily non-surgical management of osteomyelitis of the foot in diabetes. Diabetologia 2008;51(6):962-7.
3. Embil JM, Rose G, Trepman E, et al. Oral antimicrobial therapy for diabetic foot osteomyelitis. Foot Ankle Int 2006; 27(10):771-9.
4. Senneville E, Lombart A, Beltrand E, et al. Outcome of diabetic foot osteomyelitis treated nonsurgically: a retrospective cohort study. Diabetes Care 2008;31(4):637-42.
5. Neut D, van der Mei HC, Bulstra SK, et al. The role of small-colony variants in failure to diagnose and treat biofilm infections in orthopedics. Acta Orthop 2007;78(3):299-308.
6. Henke PK, Blackburn SA, Wainess RW, et al. Osteomyelitis of the foot and toe in adults is a surgical disease: conservative management worsens lower extremity salvage. Ann Surg 2005;241(6):885-92.
7. Bamberger DM, Daus GP, Gerding, DN. Osteomyelitis of diabetic patients, long term results, prognostic factors, and the role of antimicrobial and surgical therapy. Am J Med 1987; 83(4):653-660.
8. Haas DW, McAndrew MP. Bacterial osteomyelitis in adult: evolving considerations in diagnosis and treatment. Am J Med 1996; 101(5):550-561.
9. Lew DP, Waldvogel FA. Osteomyelitis. New Engl J Med. 1997; 336(14):999-1007.
10. Lipsky BA. Osteomyelitis of the foot in diabetic patients. Clin Infect Dis 1997; 25(6):1318-1326.
11. Jeffcoate WJ, Lipsky BA. Controversies in diagnosing and managing osteomyelitis of the foot in diabetes. Clin Infect Dis. Aug 1 2004;39 Suppl 2:S115-122.
12. Senneville E, Yazdanpanah Y, Cazaubiel M, et al. Rifampin-ofloxacin oral regimen for the treatment of mild to moderate diabetic foot osteomyelitis. J Antimicrob Chemother 2001; 48(6):927-30
13. Mah TF, Pitts B, Pellock B, Walker GC, Stewart PS, O’Toole GA. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 2003; 426(6964):306-10.
14. Widmer AF. New developments in diagnosis and treatment of infection in orthopedic implants. Clin Infect Dis 2001; 33: S94-106.
15. Jefferson KK, Goldmann DA, Pier GB. Use of confocal microscopy to analyze the rate of vancomycin penetration through Staphylococcus aureus biofilms. Antimicrob Agents Chemother 2005; 49(6):2467-73.
16. Cochran WL, Suh SJ, McFeters GA, Stewart PS. Role of RpoS and AlgT in Pseudomonas aeruginosa biofilm resistance to hydrogen peroxide and monochloramine. J Appl Microbiol 2000; 88(3):546-53.
17. Cogan NG. Effects of persister formation on bacterial response to dosing. J Theor Biol 2006; 238(3):694-703.
18. Lewis K. Persister cells and the riddle of biofilm survival. Biochemistry (Mosc) 2005; 70(2):267-74.
19. Stewart PS. Mechanisms of antibiotic resistance in bacterial biofilms. Int J Med Microbiol 2002; 292(2):107-13.
20. Bergoge-Berezin E. Resistance and new antibiotic strategies. The problem with staphylococcus. Presse Med 2000; 29(37): 2018-21.
21. Proctor RA, Van Langevelde P, Kristjansson M, Maslow JN, Arbeit RD. Persistent and relapsing infections associated with small-colony variants of Staphylococcus aureus. Clin Infect Dis 1995; 20(1):95-102.
22. Looney WJ. Small-colony variants of Staphylococcus aureus. Br J Biomed Sci 2000; 57(4):317-22.